Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
about
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinomaPhase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a ParadigmDrug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.Management of pulmonary toxicity associated with targeted anticancer therapies.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.Safety of mTOR inhibitors in adult solid organ transplantation.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.Sunitinib side effects as surrogate biomarkers of efficacy.Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyRadiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.
P2860
Q28067482-14739C12-87FD-48AE-BFF2-CC611E102010Q35144264-357E1829-3CF5-4604-BC79-39AEAA04969EQ36064933-42B115FF-4C61-41B5-B042-B1A40827B521Q36494977-784CF1CE-FF37-4B10-81AB-6CC86B13AB00Q36755620-4C756C21-12DB-4637-ADFE-636D51C8E875Q37589551-9C8E4CBD-B7EA-47D4-B742-C90CBA7AF20AQ38199328-E38FC91A-EF3A-43C9-BB81-46D2ABA28FDCQ38570532-5CC587E0-09D1-484F-8A70-0F184746FBC3Q38603164-E340FBF9-3F5D-4442-8307-B5A0B43968EBQ38669190-42647E92-00F3-4722-B910-49061ADDC1E4Q38752269-11ADBCF1-ADAA-4A06-B6B7-4A7BFE46A937Q39092937-8434B5A7-B2AA-4DCC-9BCD-AE1DB6AEFE8CQ41630845-AAE5F589-07A9-412A-A7F2-980317EBF370Q45058787-C50AFCB3-FAC0-4BA1-9962-E7BBFF696DC8Q48306032-784E943B-648F-4500-AEFE-874EC1989DFDQ50898788-52020333-1A1C-461A-95F2-F58237C97C7AQ52727884-3601E963-8483-4D44-9283-D7786E6A7534
P2860
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mammalian target of rapamycin ...... ors, management, and outcomes.
@en
Mammalian target of rapamycin ...... ors, management, and outcomes.
@nl
type
label
Mammalian target of rapamycin ...... ors, management, and outcomes.
@en
Mammalian target of rapamycin ...... ors, management, and outcomes.
@nl
prefLabel
Mammalian target of rapamycin ...... ors, management, and outcomes.
@en
Mammalian target of rapamycin ...... ors, management, and outcomes.
@nl
P2093
P2860
P356
P1433
P1476
Mammalian target of rapamycin ...... ors, management, and outcomes.
@en
P2093
Bradley J Atkinson
Diana H Cauley
Eric Jonasch
Lianchun Xiao
Nizar M Tannir
Randall E Millikan
P2860
P304
P356
10.1111/BJU.12420
P577
2013-12-02T00:00:00Z